Optimal Cord Unit Specifications:
- Cryopreserved within 24 hours of collection
- nRBC count: ≤ 8×10 7
- Cell viability: ≥ 90%
- Sterility: No growth
- TNC count: ≥ 1×10 9
- Eligible for further manufacturing per FDA requirements
- Commercially consented
Additional available unit parameters
| Parameter | Range |
|---|---|
| Unit Age | 3 months – 8+ years |
| TNC count | 1 – 1.7 x 10 9 + |
| CD34+ count | 1 – 4.9 x 10 6 + |
| HLA Typing | Varied |
| Blood Group | Varied |
| Rh +/- | Varied |
| Sex | Varied |
| Ethnicity | Varied |
| CMV status | Varied |
Determining critical quality attributes of cellular starting material that are predictive of manufacturing and clinical success is essential to reduce risk in cell therapy development. There are a variety of factors that make cord blood an ideal starting material for cell therapy manufacturing. Recently published in Nature Medicine, Dr. Katy Rezvani and her group at MD Anderson shared attributes of “optimal” cord blood units (CBUs) for manufacture of cord blood derived CAR-NK cell therapies. The critical factors that were predictive of superior clinical outcomes (+30 OR, 1-year CR, 1-year PFS, and 1-year OS) were (i) time from collection to cryopreservation ≤ 24 hours and (ii) nucleated red blood cell count ≤ 8×10 7 . The authors suggest that these cord attributes are likely related to cellular stress and may also be predictive of positive outcomes of other cord-derived therapies.
Our NMDP BioTherapies Cord Blood Bank Alliance offers a single point of access to > 200,000 CBUs for allogeneic cell therapy development. We have leveraged this inventory to identify units across cord blood banks that meet the unique attributes described by the Rezvani group to make them easily available to cell therapy developers.
If you have additional unique needs and characteristics in your cord blood units, please reach out to us.
Phone:
(800) 471-4431
Email:
info@NMDPbiotherapies.com
Request a Quote for Optimal Cord Units